11/19/2026 | Press release | Distributed by Public on 11/19/2026 03:59
Today's big story: Could Anthropic Stock Fall 25%?
Gilead Sciences (GILD) stock returned 39.5% over the past year, against 11.0% for the S&P 500. The question is whether Gilead can keep growing past Biktarvy, its best-selling drug. Gilead needs that growth, because Medicare's price for Biktarvy takes effect in 2028 at about 38% below its list price. So could Gilead's HIV prevention drugs fill that gap, and how much do they sell today?
Gilead stock returned 39.5% in one year, and a gain that big can shrink fast. If much of your savings sits in this one stock, a fall would hit hard. The Trefis Income Solution pays a dividend yield about 3x the S&P 500's, and it lost less than the S&P 500 in all 9 big selloffs since 2018. See the metrics.
How Much Do Gilead's HIV Prevention Drugs Sell?
On the October 29 call, management said sales of Gilead's HIV prevention drugs are running at $4 billion a year. That counts Yeztugo plus the part of Descovy used for prevention. Combined, the two treatments hold 50% of the prevention market. Prevention sales nearly doubled from a year earlier, showing that this part of Gilead is growing fast so far.
The newer of the two is Yeztugo, a shot given twice a year. It recorded $305 million in sales during the third quarter of 2026, up 31% from the second quarter. Management expects about $1 billion of Yeztugo sales for the full year 2026, anticipating slower growth in the fourth quarter because of the holidays.
Gilead's Prevention Business Is Still Far Smaller Than Biktarvy
Biktarvy brought in $14.3 billion in fiscal 2025 out of $29.4 billion in total company revenue. Descovy generated $2.76 billion that year, up 30.5% from 2024. About 80% of Descovy is sold for prevention.
Management expects the lower Medicare price to cut Biktarvy revenue by about $1.5 billion in 2028. That figure includes knock-on effects on other U.S. buyers, such as Medicaid. The company still expects total HIV revenue to grow in 2028 against 2027. That forecast holds only if prevention treatments and Gilead's other new HIV drugs add more than Biktarvy loses.
That growth is still only a forecast, yet Gilead stock closed on November 18 just 3.2% below its highest close of the past year.
What Is Behind Gilead's 18% HIV Sales Growth?
Gilead's HIV sales reached $6.2 billion in the third quarter of 2026, rising 18% from a year earlier. A portion of that gain came from inventory. Higher prices, higher demand and an inventory build-up helped lift the total. That inventory effect should fade by year-end, since management expects a smaller build than usual in the fourth quarter.
Descovy's growth leaned on price and inventory. Its third-quarter sales climbed 49% from a year earlier, driven by higher prices and an inventory build-up. If prevention growth slows once inventory evens out, the 2028 forecast for growing HIV revenue becomes harder to meet. You would then own a stock near its high with the Biktarvy price cut still ahead.
Right now, prevention sales are climbing fast, while HIV growth after the Biktarvy cut remains only management's forecast. Gilead expects the FDA to rule on a once-weekly pill version of Yeztugo for prevention in February 2027. Gilead is also expected to report results that month. That report will show how HIV sales grow once the inventory boost fades.
With so much of Gilead's future tied to a few HIV drugs, a large position in the stock warrants an exit plan made before that news arrives.
Too Much Riding On One Stock?
If Gilead Sciences is a big part of your wealth, so are its risk and its tax bill. What's your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.
Spot an error or want more like this? Tell us in 10 seconds.